Trial Profile
The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes Inadequately Controlled With D150 Plus D759, Randomized, Double-blind, Multi-center, Parallel-group, Placebo Control, Therapeutic Confirmatory Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Lobeglitazone (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Chong Kun Dang
- 28 Aug 2018 New trial record